|
2024
|
Invention
|
A non-human transgenic animal model and a method of producing the same. Provided is a spatiotempo... |
|
2023
|
Invention
|
Small-molecule modulators of spike protein. Disclosed herein are small-molecule modulators of spi... |
|
|
Invention
|
Use of galectin-1 as immune checkpoint in preparation of tumor immunotherapy medicament and medic... |
|
|
Invention
|
Preparation method of tetrodotoxin and its analog. The present disclosure relates to a preparatio... |
|
2022
|
Invention
|
Q-coupled signaling and/or activating cells. qq signaling and/or activating cells. |
|
|
Invention
|
Microglia having car and use thereof. Provided is a recombinant adeno-associated virus (rAAV) vec... |
|
|
Invention
|
Antibodies against areg and its use.
Provided are anti-AREG antibodies or immunoreactive fragmen... |
|
|
Invention
|
Compounds as mlkl inhibitors. A substituted cyclic compound as represented by formula (I) and hav... |
|
|
Invention
|
Specific host factor of hepatitis b virus infection, and use thereof.
Provided is a host factor ... |
|
|
Invention
|
Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis. A method... |
|
|
Invention
|
Polycyclic compounds and uses thereof. Provided herein are polycyclic compounds, compositions, an... |
|
|
Invention
|
A bispecific antibody targeting gpc3 and cd47.
An isolated anti-CD47 antibody or fragment thereo... |
|
|
Invention
|
A bispecific antibody targeting gpc3 and cd47. Provided is a bispecific antibody targeting GPC3 a... |
|
2021
|
Invention
|
Recombinant aav vectors and use thereof. 1234567891010Q, rAAV vector comprising the same, and the... |
|
|
Invention
|
A molecular glue regulating cdk12-ddb1 interaction to trigger cyclin k degradation. Provided is a... |
|
|
Invention
|
Apoptosis inhibitors. The invention provides compounds that are inhibitors or covalent modifiers ... |
|
|
Invention
|
Fto inhibitors.
The invention provides compounds that inhibit FTO (fat mass and obesity), includ... |
|
|
Invention
|
Antibodies against areg and its use. Provided are anti-AREG antibodies or immunoreactive fragment... |
|
|
Invention
|
Soluble ace2 and fusion protein, and applications thereof.
A soluble ACF and a truncated form th... |
|
|
Invention
|
Soluble ace2 and fusion protein, and applications thereof. Soluble ACE2 and a truncated form ther... |
|
|
Invention
|
Specific host factor for hepatitis b virus infection and use thereof. The present invention relat... |
|
|
Invention
|
Specific host factor of hepatitis b virus infection, and use thereof. The present invention provi... |
|
2020
|
Invention
|
Cathepsin c inhibitors.
Disclosed compounds, pharmaceutical compositions are used for inhibiting... |
|
|
Invention
|
Ntcp inhibitors. The invention provides cyclosporin A analogues that are NTCP inhibitors and usef... |
|
|
Invention
|
Pyroptosis-induced immunotherapy. Pyroptosis-induced immunotherapy is effected by activating a po... |
|
|
Invention
|
Prostatitis treatment.
It relates to methods of treating prostatitis comprising administering to... |
|
|
Invention
|
Prostatitis treatment. It relates to methods of treating prostatitis comprising administering to ... |
|
|
Invention
|
Heme oxygenase-1 inducer and application thereof. The present invention relates to a heme oxygena... |
|
|
Invention
|
Method for constructing model of vitiligo and the use of the model.
Provided is a drug target fo... |
|
|
Invention
|
Drug targets for hair follicle stem cell loss and use. Provided is mechanical change sensed by me... |
|
|
Invention
|
Method for constructing model of vitiligo and the use of the model. Provided is a drug target for... |
|
|
Invention
|
Necrosis inhibitors. The invention provides amides that inhibit cellular necrosis and/or human re... |
|
|
Invention
|
Fto inhibitors. The invention provides compounds that inhibit FTO (fat mass and obesity), includi... |
|
2019
|
Invention
|
Treating male senescence. The invention provides methods of treating male reproductive senescence... |
|
|
Invention
|
Mono halogen or methyl-substituted 5-ht2b antagonists with increased activity. 2B2B2B2B. |
|
|
Invention
|
Cathepsin c inhibitors. Disclosed are compounds, pharmaceutical compositions used for inhibiting ... |
|
|
Invention
|
Animal model of idiopathic pulmonary fibrosis, its construction method and use.
The present inve... |
|
|
Invention
|
Drug target of idiopathic pulmonary fibrosis.
Provided is a drug target for idiopathic pulmonary... |
|
|
Invention
|
Prosthesis for the lung and the use thereof.
The invention relates to prosthesis for treating pu... |
|
|
Invention
|
Prosthesis for the lung and the use thereof. Prosthesis for treating pulmonary fibrosis, in parti... |
|
|
Invention
|
Animal model of idiopathic pulmonary fibrosis, its construction method and use. Provided are a me... |
|
|
Invention
|
Drug target of idiopathic pulmonary fibrosis. Provided is a drug target for idiopathic pulmonary ... |
|
|
Invention
|
Use of ntcp inhibitors in preventing and treating hepatocarcinogenesis. The invention provides us... |
|
2018
|
Invention
|
Adenosine analog and its use in regulating the circadian clock.
The present invention provides a... |
